cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
about
Knockdown of UbcH10 enhances the chemosensitivity of dual drug resistant breast cancer cells to epirubicin and docetaxel.Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.Targeting the MET pathway for potential treatment of NSCLC.Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap AnalysisPrognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy.
P2860
cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
cMET in triple-negative breast ...... set of breast cancer patients?
@en
type
label
cMET in triple-negative breast ...... set of breast cancer patients?
@en
prefLabel
cMET in triple-negative breast ...... set of breast cancer patients?
@en
P2093
P2860
P1476
cMET in triple-negative breast ...... set of breast cancer patients?
@en
P2093
John Crown
Michael J Duffy
Norma O'Donovan
Patricia B Gaule
P2860
P304
P356
10.1517/14728222.2014.938050
P407
P577
2014-08-01T00:00:00Z